InMed Pharmaceuticals Inc. Q2 FY2021 earnings call

• Acknowledged the impact of COVID-19 on operations but noted minimal initial impact, with some delays due to third-party service provider restrictions. - Achieved key clinical and business development milestones in Q2 2021, including closing an $8 million financing and a $4.5 million private placement, extending cash runway. - Highlighted achievements in therapeutic development: INM-755 Phase I trials showed safety/tolerability; INM-088 preclinical results on IOP relief and neuroprotection; IntegraSyn platform advancing with collaboration with BayMedica.

No detailed breakdown of financial performance by product segments with revenue contribution percentages provided in the transcript.

• Previously had cash runway into Q3 2021; after the private placement, will update cash runway guidance. - Plan to file clinical trial applications for INM-755 Phase II in Q2 2021 and initiate patient enrollment in H2 2021; plan to file applications for INM-088 in H1 2022 for human clinical testing.

• Impact of COVID-19 on third-party service providers causing delays in timelines. - Uncertainties in clinical trial outcomes, regulatory approvals, and commercialization of products.

Q: On the INM-755 Phase II trial, what geographical area?

A: European area selected as most cost-effective.

Q: On IntegraSyn partnerships, expected in 2021?

A: Will engage other cannabinoid manufacturers but outcomes uncertain.

Q: On G&A spending, future outlook?

A: G&A will be higher going forward due to increased costs from financings, compliance, etc.

Q: Changes to Phase II trial design based on Phase I?

A: Trial design built on Phase I learnings but no major changes.

Q: BayMedica collaboration prospects?

A: Research collaboration; results expected in H1 2021 to assess potential licensing deals.

Q: GW Pharma acquisition relevance?

A: Shows potential of cannabinoid-based pharmaceuticals, aligning with InMed's path.